Navigation Links
New antibiotic beats superbugs at their own game
Date:7/3/2008

The problem with antibiotics is that, eventually, bacteria outsmart them and become resistant. But by targeting the gene that confers such resistance, a new drug may be able to finally outwit them. Rockefeller University scientists tested the new drug, called Ceftobiprole, against some of the deadliest strains of multidrug-resistant Staphylococcus aureus (MRSA) bacteria, which are responsible for the great majority of staphylococcal infections worldwide, both in hospitals and in the community.

The research, to be published in the August 2008 issue of the journal Antimicrobial Agents and Chemotherapy and available online now, looked at how well Ceftobiprole worked against bacterial clones that had already developed resistance to other drugs. In every case, Ceftobiprole won. "It just knocked out the cells 100 percent," says the study's lead investigator, Alexander Tomasz, head of the Laboratory of Microbiology at Rockefeller.

Previous research had already shown that -- in general -- Ceftobiprole was highly effective against most clinical isolates of S. aureus. "Instead, we looked more carefully at the highly resistant cells that already occur in such clinical isolates at very low frequency -- maybe in one bacterium in every 1,000," says Tomasz. Ceftobiprole was able to kill these resistant cells.

Never before has an antibiotic been tested this way. "In the history of antibiotic development, an antibiotic arrives on the scene, and sooner or later resistant bacteria emerge," Tomasz says. "We sought to test in advance which would win this particular chess game: the new drug, or the bacteria that now cause human deaths."

In an ominous new "move" in this chess game, S. aureus strains with resistance to vancomycin (VRSA), a different class of antibiotics, also began to appear in hospitals in the United States. Ceftobiprole was also able to kill these new resistant VRSA strains.

The drug is effective because the chemists who developed Ceftobiprole managed to outwit the bacteria at their own game, Tomasz says. The broad-spectrum antibiotic was discovered by Basilea Pharmaceuticals, based in Basel, Switzerland, and is being developed in the U.S. and worldwide by Johnson & Johnson. The research was supported by Johnson & Johnson along with a grant from the U.S. Public Health Service.


'/>"/>

Contact: Joseph Bonner
bonnerj@rockefeller.edu
212-327-8998
Rockefeller University
Source:Eurekalert  

Related biology news :

1. Researchers discover new strategies for antibiotic resistance
2. UIC researchers find promising new targets for antibiotics
3. Alternative methods proposed to detect pesticides and antibiotics in water and natural food
4. Manure management reduces levels of antibiotics and antibiotic resistance genes
5. Poultry workers at increased risk of carrying antibiotic-resistant E. coli
6. High degree of resistance to antibiotics in Arctic birds
7. Unique fungal collection could hold key to future antibiotics
8. NIH awards $6.5 million grant to UT Southwestern to develop new antibiotic
9. UIC scientists discover how some bacteria survive antibiotics
10. Researchers uncover mechanism of action of antibiotic able to reduce neuronal cell death in brain
11. Test of bacteria toxin delivery system could pave way for new antibiotic drugs
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New antibiotic beats superbugs at their own game
(Date:4/13/2017)... April 13, 2017 According to a new market ... Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, ... Market is expected to grow from USD 14.30 Billion in 2017 to ... of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
Breaking Biology News(10 mins):
(Date:6/20/2017)... ... June 20, 2017 , ... National executive ... leader with extensive assay development and biomarker expertise, as VP of Scientific Affairs ... CRO specializing in bio-analytical assay development and sample testing services. The organization acts ...
(Date:6/20/2017)... , ... June 20, 2017 , ... ... discovery of antibody therapeutics from millions-diverse immune repertoires, announces launch of its new ... Diego, California. Dave Johnson, PhD, CEO of GigaGen, will present on Surge at ...
(Date:6/19/2017)... ... June 19, 2017 , ... ... development reported today that it is launching two new additions of its award-winning ... demonstrating new capabilities at the DIA 2017 Annual Meeting in Chicago, IL, June ...
(Date:6/19/2017)... ... 2017 , ... A colony of healthy honey bees is like a superorganism--individual ... and nectar containing nutrients necessary for growth and survival. Better nutrition gives the colony ... point to a decline in honey bee health. Sick and weakened bees diminish the ...
Breaking Biology Technology: